Gene Therapy


  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Beam’s base editing therapy for sickle cell hits goal in pivotal trial

    The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.

    By • Nov. 10, 2026
  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis reveals cancer cases possibly linked to gene therapy Zolgensma

    The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”

    By • Updated Nov. 9, 2026
  • Trendline

    Gene Therapy

    Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges. 

    By BioPharma Dive staff
  • 3D Rendering of a Natural Killer Cell (NK Cell) destroying a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Artiva to quit autoimmune cell therapy work, cut staff after patient deaths

    The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.

    By • Oct. 27, 2026
  • Exterior building picture of the Merck KGaA Life Science site in Burlington, U.S.
    Image attribution tooltip
    Courtesy of Merck KGaA
    Image attribution tooltip

    Merck KGaA bets on RNAi with $1.3B Silence buyout

    The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

    By • Oct. 19, 2026
  • Rendered illustration of human DNA
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biogen-backed Estuary nabs $93M for kidney disease gene therapy

    The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."

    By • Oct. 16, 2026
  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Belgian startup revives Galapagos CAR-T research

    Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

    By • Oct. 15, 2026
  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Parkinson’s cell therapy developer files to go public

    Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.

    By • Oct. 12, 2026
  • An illustration of CRISPR-cas9 gene editing
    Image attribution tooltip
    del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
    Image attribution tooltip
    Gene editing

    Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

    Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives” instead.

    By Kristin Jensen • Oct. 7, 2026
  • dna helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Beam sues 2 biotechs, alleging theft of base editing trade secrets

    Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

    By • Sept. 29, 2026
  • An illustration of DNA against a blue abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    UniQure tumbles with latest data for Huntington’s gene therapy

    Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."

    By • Sept. 29, 2026
  • An illustration of the kidneys, colored red and blue.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche, Ionis RNA drug scores in kidney disease study

    The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers. 

    By • Sept. 23, 2026
  • A close-up of a person's brown eye.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Beacon eye gene therapy hits mark in late-stage study

    Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.

    By • Sept. 21, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

    Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

    By BioPharma Dive staff • Sept. 18, 2026
  • An illustration of a gene being inserted into a helix strand.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

    Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.

    By • Sept. 14, 2026
  • Gloved workers supervise rows of glass bottles on a pharmaceutical production line.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    mRNA cancer vaccines’ biggest barriers to market

    Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

    By Alexandra Pecci • Sept. 11, 2026
  • An exterior photo of Seattle Children's Hospital.
    Image attribution tooltip
    Courtesy of Seattle Children's Hospital
    Image attribution tooltip

    BrainChild hauls in $116M to make cell therapies for childhood brain cancers

    Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.

    By • Sept. 8, 2026
  • A technician in protective clothing stands beside manufacturing equipment in a pharmaceutical laboratory.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The hidden scale-out problem behind CAR-T’s growth

    CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.

    By Sy Mukherjee • Sept. 3, 2026
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

    Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

    By • Sept. 2, 2026
  • A sign for the Food And Drug Administration is seen
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

    The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S. regulators.

    By Kristin Jensen • Sept. 2, 2026
  • CAR-T cell therapy uses the body as a manufacturing site to fight cancer
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

    The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects pushed Bristol Myers to voluntarily pause its zola-cel program.

    By • Updated Sept. 1, 2026
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Safety concerns spur FDA to again halt testing of Regenxbio gene therapy

    Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.

    By • Aug. 24, 2026
  • A sign reading Ultragenyx hangs on the side of a glass office building.
    Image attribution tooltip
    Sundry Photography via Getty Images
    Image attribution tooltip

    Ultragenyx, after setbacks, nabs first gene therapy approval

    The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.

    By Kristin Jensen • Aug. 20, 2026
  • A rendering of an adeno-associated virus, colored blue-green, on a black background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    PTC takes a chance on Sangamo’s Fabry disease gene therapy

    Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.

    By Kristin Jensen • Aug. 13, 2026
  • gene editing crispr cartoon
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A // Gene editing

    Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

    The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years. 

    By • Aug. 10, 2026
  • A Moderna logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Vaccines

    FDA approves Moderna’s mRNA flu vaccine

    The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.

    By • Aug. 6, 2026